Cargando…

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

PURPOSE: The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML). The objective of this study was to determine whether this intervention would be co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arenaza, Ainhoa, Diez, Raúl, Esteve, Jordi, Di Nicolantonio, Roberta, Gostkorzewicz, Joana, Martínez, Carlos, Martínez Llinàs, Diana, Martinez-Lopez, Joaquin, Montesinos, Pau, Moure-Fernández, Aída, Sierra, Jorge, Vinent, Joan Lluís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859089/ https://www.ncbi.nlm.nih.gov/pubmed/32009807 http://dx.doi.org/10.2147/CEOR.S222879

Ejemplares similares

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
por: Sierra, Jorge, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2021)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

Midostaurin-Related Interstitial Lung Injury in FLT3(+) Acute Myeloid Leukemia Post-Allogeneic Transplant
por: Vaidya, Poorva, et al.
Publicado: (2019)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
por: He, Shujiao, et al.
Publicado: (2022)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
por: Gómez-Casares, María Teresa, et al.
Publicado: (2017)

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias
por: Lipka, D B, et al.
Publicado: (2016)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
por: Weisberg, Ellen, et al.
Publicado: (2017)

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
por: Lu, Hao, et al.
Publicado: (2022)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
por: Menna, Pierantonio, et al.
Publicado: (2023)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
por: Cattaneo, Chiara, et al.
Publicado: (2022)

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
por: Weinbergerová, Barbora, et al.
Publicado: (2023)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
por: Cremer, Anjali, et al.
Publicado: (2023)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

P586: POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING
por: Joisten, Carolin, et al.
Publicado: (2023)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s1t3tjqosbjsst6nk0ii456jph